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Abstract. The atypical antipsychotic drug clozapine has multiple pharmacological 
actions, some of which, including 5-hydroxytryptamine (5-HT2) and histamine (H1) 
receptor antagonist effects, are shared by the non-selective 5-HT receptor antagonist 
cyproheptadine. Atypical antipsychotics have a characteristic profile of action on 
operant behaviour maintained by progressive-ratio schedules, as revealed by Killeen‟s 
(1994) mathematical model of scheduled controlled behaviour. These drugs increase 
the values of a parameter that expresses the „incentive value‟ of the reinforcer (a) and 
a parameter that is inversely related to the „motor capacity‟ of the organism (δ). This 
experiment examined the effects of acute treatment with cyproheptadine and 
clozapine on performance on a progressive-ratio schedule of food reinforcement in 
rats; the effects of a conventional antipsychotic, haloperidol, and two drugs with food 
intake-enhancing effects, chlordiazepoxide and Δ9-tetrahydrocannabinol (THC), were 
also examined. Cyproheptadine (1, 5 mg kg
-1
) and clozapine (3.75, 7.5 mg kg
-1
) 
increased a and δ. Haloperidol (0.05, 0.1 mg kg-1) reduced a and increased δ. 
Chlordiazepoxide (3, 10 mg kg
-1
) increased a  but reduced δ. THC (1, 3 mg kg-1) had 
no effect. Interpretation based on Killeen‟s (1994) model suggests that cyproheptadine 
and clozapine enhanced the incentive value of the reinforcer and impaired motor 
performance. Motor impairment may be due to sedation (possibly reflecting H1 
receptor blockade). Enhancement of incentive value may reflect simultaneous 
blockade of H1 and 5-HT2 receptors, which has been proposed as the mechanism 
underlying the food intake-enhancing effect of cyproheptadine. In agreement with 
previous findings, haloperidol impaired motor performance and reduced the incentive 
value of the reinforcer. Chlordiazepoxide‟s effect on a is consistent with its food 
intake-enhancing effect. 
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Introduction 
It is generally agreed that „conventional‟ antipsychotic drugs, including the 
phenothiazines and butyrophenones, are less effective in combating the negative 
symptoms of schizophrenia (anhedonia, avolition, flattened affect) than they are in 
suppressing positive psychotic symptoms (hallucinations, delusions). Indeed, there is 
evidence that conventional antipsychotics may have an adverse effect on motivation in 
man, as they are known to do in animals  (Wise 1982, 2006; King and Waddington 
2004). In contrast, „atypical‟ antipsychotics, such as clozapine, which have a lower 
propensity to induce extrapyramidal side-effects than conventional antipsychotics, are 
less liable to induce negative symptoms, and in some cases may even help to alleviate 
these symptoms by enhancing motivation (Müller-Spahn 2002; Corrigan et al. 2003).  
An adverse effect of conventional antipsychotics on motivation in animals has 
been recognized for many years (Wise 1982). For example, operant behaviour 
maintained by food or psychostimulant self-administration is suppressed by 
conventional antipsychotics, and it has been proposed that this effect is caused by a 
reduction of the incentive value of primary reinforcers (Wise 1982, 2006). Less is 
known about the effects of atypical antipsychotics on motivation and reinforcement 
processes; however there is evidence that these drugs enhance food intake in rodents 
(Hartfield et al. 2003) as they do in humans (Meltzer et al. 2003), and that they may 
increase the incentive value of food in operant behaviour paradigms (Mobini et al. 
2000; Cilia et al. 2001; Zhang et al. 2005a, 2005b; see below). 
The principal pharmacological action of conventional antipsychotics is the 
blockade of D2 dopamine receptors (Seeman et al. 1976; Kapur et al. 2000), and it has 
been proposed that the adverse effects of these drugs on motivation reflect their ability 
to disrupt dopaminergic mechanisms in limbic structures (Wise 1982, 2006). Atypical 
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antipsychotics,however, have complex and varied pharmacological profiles, and their 
principal mode(s) of action remain in dispute. Clozapine, the most extensively studied 
drug of this class, has a relatively low affinity for D2 dopamine receptors, but a high 
affinity for several subtypes of 5-hydroxytryptamine (5-HT) receptor, most notably 5-
HT2A receptors (Bymaster et al. 1996). The combination of D2 and 5-HT2A receptor 
antagonism has been proposed as the basis of clozapine‟s favourable therapeutic 
profile (Meltzer et al. 1989; Ichikawa et al. 2001), leading to the suggestion that the 
combination of a conventional antipsychotic with a 5-HT2 receptor antagonist might 
offer some therapeutic advantages over treatment with a conventional antipsychotic 
alone in the management of the negative symptoms of schizophrenia (Meltzer et al. 
1995). Clinical investigations of this proposal have yielded mixed results: some 
studies found that the 5-HT receptor antagonist cyproheptadine (which also has high 
affinity at H1 receptors (Goudie et al. 2007), produced an improvement of negative 
symptomatology in schizophrenic patients concurrently treated with a conventional 
antipsychotic (Silver et al. 1989; Bacher et al. 1994; Akhondzadeh et al. 1999), 
whereas others found no significant effect (Silver et al. 1991; Lee et al. 1995; 
Chaudhry et al. 2002).  
There have been several preclinical studies comparing the behavioural effects 
of atypical antipychotics and cyproheptadine. Comparisons of clozapine and 
cyproheptadine are of particular interest because these drugs have similar profiles of 
affinity for different subtypes of 5-HT receptor, both drugs having particularly high 
affinity for 5-HT2A and H1 receptors (Bymaster et al. 1996; Young et al. 2005; Goudie 
et al. 2007). These drugs share many behavioural effects. Both drugs stimulate food 
intake and induce weight gain, have sedative effects, and reverse the suppressant 
effect of punishment on operant responding in rats (Ketelaars and Bruinvels 1989; 
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Moore et al. 1992; Hartfield et al. 2003). Recently it has been found that the two drugs 
show generalization and cross-tolerance in a drug discrimination paradigm (Goudie et 
al. 2007). The present experiment extended these observations by comparing the 
effects of clozapine and cyproheptadine on operant behaviour in rats, with the aim of 
establishing whether these drugs also share the ability to enhance the incentive value 
of a food reinforcer. 
Several methods have been proposed to assess the effects of drugs on the 
incentive value of reinforcers. One such method is the progressive-ratio schedule, in 
which the number of responses required to obtain a reinforcer increases progressively 
with successive reinforcers (Hodos 1961; Hodos and Kalman 1963). The ratio at 
which the subject stops responding (the breakpoint) (Hodos 1961), or the highest ratio 
completed within a time-constrained session (Aberman et al. 1998; Hamill et al. 
1999), has been regarded as a measure of incentive value (Hodos 1961; Cheeta et al. 
1995) or the organism‟s motivation to obtain a reinforcer (Barr and Philips 1998). 
However, doubts have been raised about the use of the breakpoint as an index of 
incentive value (Arnold and Roberts 1997; Mobini et al. 2000; Ho et al. 2003; Killeen 
et al. 2009; Rickard et al. 2009). This measure is sensitive not only to changes in 
reinforcer value but also to non-motivational variables such as the height of the 
operant lever (Aberman et al. 1998; Skjoldager et al. 1993) and the ratio step size 
(Stafford and Branch 1998). It has also been noted that there is no consensus about the 
definition of the breakpoint (Arnold and Roberts 1998; Killeen et al. 2009), and 
reliance upon a single datum point determined by the subject‟s persistence in 
responding can be problematic in the case of drugs with short plasma half-lives 
(Arnold and Roberts 1997; Stafford et al. 1998; Rowlett 2000; Killeen et al. 2009). 
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Quantitative models of schedule-controlled behaviour enable some of the 
problems related to the breakpoint to be circumvented, and may offer a more reliable 
basis for discriminating between the effects of drugs on incentive value and motor 
functions. One such model is Killeen‟s Mathematical Principles of Reinforcement 
(MPR: Killeen 1994; Killeen and Sitomer 2001). According to this model, schedule-
controlled responding is determined by three factors: a general excitatory effect of  
reinforcers on behaviour, a biological constraint on responding imposed by the 
response requirement and the physical capacities of the organism, and the efficiency 
with which particular reinforcement schedules couple operant responses to 
reinforcers. In the case of ratio schedules, in which N responses are required to obtain 
a reinforcer, response rate, R, is predicted by the following equation:    
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N
    [1] 
 
 
where  („currency‟) represents the extent to which the strengthening effect of the 
reinforcer is focussed on the most recent response,  („response time‟) is the minimum 
time needed to execute a response, and a („specific activation‟) is the time for which a 
reinforcer is able to activate behaviour. Equation 1 defines an „inverted-U‟ function. β 
influences the horizontal location of the peak of the function, δ determines the height 
of the peak, 1/δ being the theoretical maximum response rate, and a specifies the 
slope of the descending limb (slope = -1/a). It has been suggested that the last of these 
parameters, a, may provide an index of reinforcer efficacy (Killeen and Sitomer 2003; 
Reilly 2003), a proposal that has found empirical support in demonstrations of the 
sensitivity of this parameter to manipulation of reinforcer size and quality (Bizo and 
Killeen 1997; Reilly 2003; Rickard et al. 2009).  
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Equation 1 was developed to describe performance on fixed- and variable-ratio 
schedules; however it also provides a good description of overall response rates on 
progressive-ratio schedules (Ho et al. 2003; Kheramin et al. 2005; Zhang et al. 2005a, 
2005b; Bezzina et al. 2008a, 2008b; Killeen et al. 2009; Rickard et al. 2009). 
Application of Equation 1 to progressive-ratio schedule performance has been used to 
detect the effects of brain lesions and centrally-acting drugs on motivational and 
motor-related processes (Mobini et al. 2000; Ho et al. 2003; Reilly 2003; Kheramin et 
al. 2005; Zhang et al. 2005a, 2005b; Bezzina et al. 2008a, 2008b).  
A recent study of the effect of reinforcer size on progressive-ratio schedule 
performance (Rickard et al. 2009) showed that while Equation 1 provided a good 
description of overall response rate, its fit to the running response rate (response rate 
calculated after exclusion of the post-reinforcement pause) was less satisfactory. 
Running response rate was, however, well described by the logistic function 
 
  R = Ri /(1+[N/b]
c
)        [2] 
 
where Ri is a parameter expressing the initial (maximum) response rate, b expresses 
the rate of decay of the function, and the exponent c modulates the curvature of the 
function. Rickard et al. (2009) found that b was monotonically related to reinforcer 
size, while Ri and c were unaffected by changes in reinforcer size. 
 Atypical antipsychotics have a profile of action on the parameters of Equation 
1 which distinguishes them from conventional antipsychotics. Clozapine and other 
atypical antipsychotics (e.g. quetiapine, olanzapine and ziprasidone) increase both a 
and δ (Mobini et al. 2000; Zhang et al. 2005a, 2005b), consistent with an increase in 
the incentive value of the reinforcer and an impairment of motor function. 
Conventional antipsychotics (e.g., haloperidol, pimozide, raclopride and cis-
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flupenthixol) also increase δ, but unlike the atypical antipsychotics they either have no 
effect on a or reduce the value of this parameter (Mobini et al. 2000; Zhang et al. 
2005a).  
 The present experiment compared the effects of cyproheptadine and clozapine 
on the parameters of Equations 1 and 2. Based on the similarity of these drugs‟ effects 
on food intake and the finding that these two drugs display behavioural cross-
tolerance and generalization in drug discrimination studies (see above), it was 
predicted that cyproheptadine, like clozapine, would increase the values of a and δ. 
For comparison, the effects of the conventional antipsychotic haloperidol and two 
drugs with well documented food intake-enhancing effects, chlordiazepoxide 
(Berridge and Treit 1986; Freet et al. 2006) and Δ9-tetrahydrocannabinol (THC) 
(Abel, 1975; Kirkham and Williams 2001; Koch 2001; Williams and Kirkham 2002), 
were also examined.  
 
Methods 
The experiment was carried out in accordance with UK Home Office regulations 
governing experiments on living animals. 
 
Subjects 
Female Wistar rats approximately 4 months old and weighing 250-300 g at the start of 
the experiment were used. They were housed under a constant cycle of 12 h light and 
12 h darkness (light on 0600-1800 hours), and were maintained at 80% of their initial 
free-feeding body weights throughout the experiment by providing a limited amount 
of standard rodent diet after each experimental session. Tap water was freely available 
in the home cages. 
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Apparatus 
The rats were trained in operant conditioning chambers (Campden Instruments 
Limited, Sileby, UK) of internal dimensions 20 cm × 23 cm × 22.5 cm. One wall of 
the chamber contained a recess into which a motor-operated dispenser could deliver 
45-mg food pellets (TestDiet products, formula 5TUM). An aperture was situated 5 
cm above and 2.5 cm to one side of the recess (left or right, counterbalanced across 
rats), through which a motor-driven retractable lever could be inserted into the 
chamber. The lever could be depressed by a force of approximately 0.2 N. The 
chamber was enclosed in a sound-attenuating chest; masking noise was provided by a 
rotary fan. An Acorn microcomputer programmed in Arachnid BASIC (CeNeS Ltd, 
Cambridge, UK), located in an adjoining room, controlled the schedules and recorded 
the behavioural data. 
 
Behavioural training 
Two weeks before starting the experiment, the food deprivation regimen was 
introduced and the rats were gradually reduced to 80% of their free-feeding body 
weights. Then they were trained to press the lever for the food-pellet reinforcer, and 
were exposed to a fixed-ratio 1 schedule for 3 days followed by fixed-ratio 5 for a 
further 3 days. Thereafter, they underwent daily training sessions under the 
progressive-ratio schedule. The progressive-ratio schedule was based on the following 
exponential progression: 1, 2, 4, 6, 9, 12, 15, 20, 25, 32, 40, 50, ..., derived from the 
formula (5×e
0.2n
)-5, rounded to the nearest integer, where n is the position in the 
sequence of ratios (Roberts and Richardson 1992). Sessions took place at the same 
time each day during the light phase of the daily cycle (between 0800 and 1300 hours) 
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7 days a week. At the start of each session, the lever was inserted into the chamber; 
the session was terminated by withdrawal of the lever 50 min later.  
 
Drug treatment 
The drug treatment regimen started after 90 sessions of preliminary training under the 
progressive-ratio schedule. Injections of drugs were given on Tuesdays and Fridays, 
and injections of the vehicle alone on Mondays and Thursdays; no injections were 
given on Wednesdays, Saturdays or Sundays. Different groups of rats were used to 
test the various drugs (see below); each rat was tested five times with each dose of the 
drug, the order of doses being counterbalanced across animals according to a Latin 
square design. Drugs were injected intraperitoneally (2.5 ml kg
-1
; 25-gauge needle) 30 
min before the start of the experimental session. Doses were calculated from the 
weights of the salts. Cyproheptadine hydrochloride (1 and 5 mg kg
-1
; n = 12) and 
chlordiazepoxide hydrochloride (3 and 10 mg kg
-1
; n = 12) were dissolved in sterile 
0.9% sodium chloride solution. Clozapine (3.75 and 7.5 mg kg
-1
; n = 15) and 
haloperidol (0.05 and 0.1 mg kg
-1
; n = 11) were dissolved in 0.1 M tartaric acid, 
buffered to pH 5.5 and diluted with sterile 0.9% sodium chloride to give the desired 
concentration. Δ9-tetahydrocannabinol (THC, 1 and 3 mg kg-1; n = 12) was dissolved 
in a mixture of ethanol and Tween (1:1) and diluted with sterile water to give the 
desired concentration. Cyproheptadine and THC were obtained from Tocris 
Bioscience, Bristol, UK; clozapine, haloperidol and chlordiazepoxide were obtained 
from Sigma Chemical Company, Poole, UK. The doses of clozapine and haloperidol 
were chosen on the basis of previous findings of the effects of these drugs on 
progressive-ratio schedule performance (Mobini et al. 2000; Zhang et al. 2005a), the 
doses of cyproheptadine were chosen on the basis of previous findings with the drug 
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discrimination paradigm (Goudie et al. 2007), and the doses of chlordiazepoxide and 
THC were chosen on the basis of their effects on feeding behaviour (Berridge and 
Treit 1986; Koch 2001; Williams and Kirkham 2002; Freet et al. 2006). 
 
Data analysis 
The data obtained with each drug were analysed separately. Only the data obtained 
from the sessions in which injections had been given were used in the analysis.  
Peak response rate. The highest overall response rate (see below) attained 
during performance on the progressive-ratio schedule was compared between 
treatments by repeated-measures one-way analysis of variance, followed, in the case 
of a significant effect of treatment, by comparison of each dose of the drug with the 
vehicle-alone treatment using Dunnett‟s test. 
 Highest completed ratio and breakpoint. The breakpoint was defined as the 
last ratio to be completed before 5 minutes elapsed without any responding. In most 
cases, this was identical to the highest ratio completed in the session. However, in the 
case of some rats, the breakpoint criterion was sometimes not met within the 
50-minute session. Therefore, both the highest completed ratio and breakpoint were 
compared between treatment conditions using analyses of variance followed by 
multiple comparisons with the vehicle-alone condition using Dunnett‟s test. In the 
case of the breakpoint, sessions in which the breakpoint criterion was not met were 
excluded from the analysis.  
Overall response rate. Overall response rate was calculated for each ratio by 
dividing the number of responses by the total time taken to complete the ratio, 
including the post-reinforcement pause, measured from the end of the preceding 
reinforcer delivery until the emission of the last response of the ratio (Bizo and 
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Killeen 1997). The first ratio (a single response) and any ratios that had not been 
completed at the end of the session were excluded from the analysis. The raw data 
were analysed by two-factor analysis of variance (treatment condition × ratio) with 
repeated measures on both factors. Equation 1 was fitted to the overall response rate 
data from each rat under each treatment condition using an iterative least-squares 
method (SigmaPlot, Version 8.0), and the estimated values of the parameters β, δ and 
a were derived; goodness of fit was expressed as r
2
, the proportion of the data 
variance accounted for by the equation. In agreement with previous findings (Mobini 
et al. 2000; Ho et al. 2003; Zhang et al. 2005a, 2005b; Bezzina et al. 2008a, 2008b; 
Rickard et al. 2009), examination of the data revealed that in some rats very low 
response rates were generated under the highest ratios, which did not conform to 
Equation 1. Therefore the equation was fitted to each rat‟s data after exclusion of 
these low rates using the following operational criterion (Mobini et al. 2000). Points 
were removed successively, starting from the highest ratio completed, when the curve-
fitting routine generated an abscissa intersection point (a/δ) which lay to the left of the 
rightmost empirical datum point; such an intersection implies a negative predicted 
response rate, which is impossible empirically and specifically precluded by the model 
(see above, Equation 1). A fit was accepted when the predicted response rates for all 
the surviving data points had positive values. This procedure seldom eliminated more 
than one datum point from the data sets derived from individual rats. The estimates of 
the three parameters of Equation 1 (a, δ and β) were analysed in the same way as the 
peak response rate (see above).  
Running response rate. Running rate was calculated by dividing the number of 
responses by the „run-time‟ (i.e. the time taken to complete the ratio, excluding the 
post-reinforcement pause: Bizo et al. 2001). The data were analysed as described 
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above. Equation 2 was fitted to the running rate data from the individual rats and the 
parameter estimates were analysed in the same way as the parameters of Equation 1.  
Because the number of ratios completed within a session under a progressive-
ratio schedule differs among individual subjects, analyses of variance of the raw 
response rates included only those ratios that were completed by at least 75% of the 
rats in each group under each treatment condition (ratios up to and including 62 in the 
case of the haloperidol series and up to and including 118 in the case of all other 
drugs), missing values being filled using the value obtained in the highest ratio 
completed by the subject in question (Rickard et al. 2009). (Note that this limitation 
did not apply to the quantitative analysis of response rates using Equations 1 and 2, 
which entailed fitting functions to the data from individual rats.)  
A significance criterion of P<0.05 was adopted in all statistical analyses. 
 
Results 
Cyproheptadine (n=12) 
 Peak response rate. The mean (± SEM) data are shown in Table 1. There was 
a significant effect of treatment [F(2,22) = 19.7, P<0.001], peak response rate being 
significantly reduced by the higher dose of cyproheptadine. 
 Highest completed ratio and breakpoint. The mean (± SEM) data are shown in 
Table 1. There was a significant effect of treatment on the highest completed ratio 
[F(2,22) = 10.7, P<0.01], the ratio being significantly increased by both doses of the 
drug. The breakpoint was also affected [F(2,22) = 4.0, P<0.05], the effect of the 
higher dose being statistically significant, and there was a dose-related reduction of 
the proportion of sessions in which the breakpoint criterion was reached [F(2,22) = 
18.6, P<0.001]. 
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 Overall response rate. The group mean data under each treatment condition 
are shown in Fig. 1 (left-hand panel). Response rate tended to be reduced in the case 
of lower ratios and increased in the case of higher ratios by the higher dose of 
cyproheptadine. Analysis of variance revealed significant main effects of treatment 
[F(2,22) = 11.6, P<0.001] and ratio [F(15,165) = 16.1, P<0.001] and a significant 
treatment × ratio interaction [F(30,330) = 2.9, P<0.001]. The fits of Equation 1 to the 
group mean data accounted for >85% of the total variance (vehicle: r
2
 = 0.98; 
cyproheptadine 1 mg kg
-1
: r
2
 = 0.95; 5 mg kg
-1
: r
2
 = 0.86). The parameters of 
Equation 1 are shown in Table 2. Cyproheptadine significantly increased the „specific 
activation‟ parameter, a [F(2,22) = 9.1, P<0.001] and the „response time‟ parameter, δ 
[F(2,22) = 12.7, P<0.001], the effect of the higher dose being significant in each case. 
There was no significant effect of cyproheptadine on the „currency‟ parameter, β 
[F(2,22) = 1.3, P>0.2]. 
 Running response rate. The group mean data under each treatment condition 
are shown in Fig. 1 (right-hand panel). Running rate tended to be reduced in the case 
of lower ratios by both doses of cyproheptadine. Analysis of variance revealed 
significant main effects of treatment [F(2,22) = 14.7, P<0.001] and ratio [F(15,165) = 
81.3, P<0.001] and a significant treatment × ratio interaction [F(30,330) = 1.5, 
P<0.05]. The fits of Equation 2 to the group mean data accounted for >90% of the 
total variance (vehicle: r
2
 = 0.97; cyproheptadine 1 mg kg
-1
: r
2
 = 0.98; 5 mg kg
-1
: r
2
 = 
0.96). The parameters of Equation 2 are shown in Table 3. Cyproheptadine 
significantly reduced the „initial response rate‟ parameter, Ri [F(2,22) = 5.4, P<0.05], 
the effect of the higher dose being statistically significant. There was no significant 
effect of cyproheptadine on the „decay‟ parameter, b  [F(2,22) = 2.4, NS], or the 
„exponent‟ parameter, c [F(2,22) = 1.8, NS]. 
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Clozapine (n=15) 
 Peak response rate. There was a significant effect of treatment [F(2,28) = 
10.2, P<0.001], peak response rate being significantly reduced by the higher dose of 
clozapine (Table 1). 
Highest completed ratio and breakpoint. Clozapine had no significant effect 
on either measure [highest completed ratio: F(2,28) = 2.6, NS; breakpoint: F<1] 
(Table 1). 
 Overall response rate. Clozapine tended to reduce overall response rate under 
the lower ratios and increase it under the higher ratios (Fig. 2, left-hand panel). 
Analysis of variance revealed significant main effects of treatment [F(2,28) = 10.3, 
P<0.001] and ratio [F(15,210) = 7.3, P<0.001] and a significant treatment × ratio 
interaction [F(30,420) = 3.1, P<0.001]. Equation 1 accounted for >85% of the total 
variance (vehicle: r
2
 = 0.88; clozapine 3.75 mg kg
-1
: r
2
 = 0.93; 7.5mg kg
-1
: r
2
 = 0.92). 
Analysis of the parameters of Equation 1 (Table 2) showed that a was increased by 
clozapine [F(2,28) = 10.9, P<0.001], the effects of both doses being statistically 
significant; δ was increased by clozapine [F(2,28) = 3.4, P<0.05], the effect of 7.5 mg 
kg
-1
 being statistically significant; β was also increased by clozapine [F(2,28) = 3.4, 
P<0.05], the effect of 7.5 mg kg
-1
 being statistically significant. 
 Running response rate. The group mean data are shown in Fig. 2 (right-hand 
panel). The higher dose of clozapine reduced response rates in the case of lower 
ratios. Analysis of variance revealed significant main effects of treatment [F(2,28) = 
6.9, P<0.01] and ratio [F(15,210) = 74.8, P<0.001] and a significant treatment × ratio 
interaction [F(30,420) = 1.8, P<0.05]. Equation 2 accounted for >90% of the total 
variance (vehicle: r
2
 = 0.98; clozapine 3.75 mg kg
-1
: r
2
 = 0.97; 7.5mg kg
-1
: r
2
 = 0.97). 
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Analysis of the parameters of Equation 2 (Table 3) showed that clozapine significantly 
reduced Ri [F(2,22) = 5.2, P<0.05], the effect of the higher dose being statistically 
significant. There was no significant effect of clozapine on b [F<1] or c [F<1]. 
  
Haloperidol (n=11) 
 Peak response rate. There was a significant effect of treatment [F(2,20) = 
13.0, P<0.001], peak response rate being significantly reduced by the higher dose of 
haloperidol (Table 1). 
 Highest completed ratio and breakpoint. Haloperidol reduced the highest 
completed ratio [F(2,20) = 23.4, P<0.001], the effects of both doses being statistically 
significant. The breakpoint was also reduced [F(2,20) = 29.8, P<0.001], the effect of 
the both doses being statistically significant, and there was a reduction of the 
proportion of sessions in which the breakpoint criterion was reached [F(2,2) = 7.7, 
P<0.01]. (Table 1). 
 Overall response rate. There was a dose-dependent suppression of overall 
response rate (Fig. 3, left-hand panel). There were significant main effects of 
treatment [F(2,20) = 70.5, P<0.001] and ratio [F(11,110) = 14.4, P<0.001] and a 
significant treatment × ratio interaction [F(22,220) = 8.2, P<0.001]. Equation 1 
accounted for >90% of the total variance (vehicle: r
2
 = 0.97; haloperidol 0.05 mg kg
-1
: 
r
2
 = 0.93; 0.1mg kg
-1
: r
2
 = 0.92). Analysis of the parameters of Equation 1 showed 
that haloperidol significantly reduced the value of a [F(2,20) = 9.2, P<0.001] and 
increased the value of δ [F(2,20) = 5.2, P<0.05];  β was not significantly affected 
[F(2,20) = 2.9, P>0.05] (Fig. 3). 
Running response rate. The group mean data are shown in Fig. 3 (right-hand 
panel). There was a dose dependent reduction of response rates. Analysis of variance 
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revealed significant main effects of treatment [F(2,20) = 27.4, P<0.001] and ratio 
[F(11,110) = 52.0, P<0.001]; the interaction term was not significant [F(22,220) = 
81.2, NS]. Equation 2 accounted for >90% of the total variance (vehicle: r
2
 = 0.98; 
haloperidol 0.05 mg kg
-1
: r
2
 = 0.99; 0.1mg kg
-1
: r
2
 = 0.99). Analysis of the parameters 
of Equation 2 (Table 3) showed that haloperidol did not significantly affect Ri 
[F(2,20) = 1.3, NS]. There was a significant reduction of b [F(2,20) = 10.4, P<0.01] 
and an increase of c [F(2,20) = 8.2, P<0.01] produced by the higher dose.  
 
Chlordiazepoxide (n=12) 
Peak response rate. There was a significant effect of treatment [F(2,22) = 6.2, 
P<0.01], peak response rate being significantly increased by the lower dose of 
chlordiazepoxide  only (Table 1). 
 Highest completed ratio and breakpoint. Chlordiazepoxide increased the 
highest completed ratio [F(2,22) = 7.7, P<0.001], the effects of both doses being 
statistically significant. The breakpoint was also increased [F(2,22) = 6.3, P<0.01], 
the effect of the lower dose being statistically significant, and there was a concomitant 
reduction of the proportion of sessions in which the breakpoint criterion was reached 
[F(2,2) = 5.3, P<0.05]. (Table 1). 
 Overall response rate. Chlordiazepoxide tended to increase overall response 
rates, this being somewhat more apparent in the case of the smaller dose (3 mg kg
-1
) 
(Fig. 4, left-hand panel). There were significant main effects of treatment [F(2,22) = 
11.6, P<0.001] and ratio [F(15,165) = 22.2, P<0.001] and a significant treatment × 
ratio interaction [F(30,330) = 1.8, P<0.01]. Equation 1 accounted for >90% of the 
total variance (vehicle: r
2
 = 0.97; chlordiazepoxide 3 mg kg
-1
: r
2
 = 0.97; 10 mg kg
-1
: r
2
 
= 0.97). Analysis of the parameters of Equation 1 (Table 2) revealed a significant 
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effect of treatment on a [F(2,22) = 5.2, P<0.05], the increase produced by 10 mg kg
-1 
being statistically significant. There was also a significant effect on δ [F(2,22) = 5.2, 
P<0.05], reflecting a reduction of this parameter produced by the 3 mg kg
-1
 dose only. 
β was not significantly affected [F(2,22) = 3.1, P>0.05]. 
Running response rate. The group mean data are shown in Fig. 4 (right-hand 
panel). The lower dose of chlordiazepoxide produced a modest increase in running 
response rate. There were significant main effects of treatment [F(2,22) = 10.3, 
P<0.001] and ratio [F(15,165) = 66.6, P<0.001]; the interaction was not significant 
[F(30,330) = 1.1, NS]. Equation 2 accounted for >90% of the total variance (vehicle: 
r
2
 = 0.97; chlordiazepoxide 3 mg kg
-1
: r
2
 = 0.98; 10 mg kg
-1
: r
2
 = 0.99). Analysis of 
the parameters of Equation 2 (Table 3) showed that chlordiazepoxide had no 
significant effect on Ri [F<1], b [F<1] or c [F(2,22) = 1.3, NS]. 
 
THC (n=12) 
Peak response rate. THC had no significant effect on the peak response rate 
[F<1] (Table 1). 
 Highest completed ratio and breakpoint. THC had no significant effect on the 
highest completed ratio [F(2,22) = 1.1, NS] or the breakpoint [F<1]. However the 
higher dose was associated with an increase of the proportion of sessions in which the 
breakpoint was achieved [F(2,22) = 4.6, P<0.05] (Table 1). 
 Overall response rate. THC had no apparent effect on overall response rate 
(Fig. 5, left-hand panel). Analysis of variance revealed a significant main effect of 
ratio [F(15,165) = 15.5, P<0.001], but no significant main effect of treatment [F(2,22) 
= 2.6, NS] and no significant interaction [F<1]. Equation 1 accounted for >90% of the 
total variance (vehicle: r
2
 = 0.97; THC 1 mg kg
-1
: r
2
 = 0.97; 3 mg kg
-1
: r
2
 = 0.97). 
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None of the parameters of Equation 1 was significantly affected by the drug [a: 
F(2,22) = 2.2, P>0.05; δ: F(2,22) = 1.6, P>0.1; β: F<1] (Table 3). 
 Running response rate. THC had no significant effect on running response rate 
(Fig. 5, right-hand panel). There was a significant main effect of ratio [F(15,165) = 
93.3, P<0.001], but no significant main effect of treatment [F<1] and no significant 
interaction [F(30,330) = 1.1, NS]. Equation 2 accounted for >90% of the total 
variance (vehicle: r
2
 = 0.98; THC 1 mg kg
-1
: r
2
 = 0.98; 3 mg kg
-1
: r
2
 = 0.99). None of 
the parameters of Equation 2 was significantly affected by THC [Ri, b, c:  all Fs<]. 
(Table 3). 
  
Discussion 
Performance on the progressive-ratio schedule was similar to that seen in many 
previous studies (Bizo and Killeen 1997; Mobini et al. 2000; Ho et al. 2003;  
Kheramin et al. 2005; Zhang et al. 2005a, 2005b; Bezzina et al. 2008a, 2008b; Killeen 
et al. 2009; Rickard et al. 2009). Overall response rate was bitonically related to ratio 
size; it increased rapidly to reach a peak, and then declined gradually as the 
response/reinforcer ratio was progressively increased. The relation between overall 
response rate and ratio size was well described by Equation 1. In agreement with a 
recent report (Rickard et al. 2009), running response rate did not conform closely to 
Equation 1, but was well described by the logistic function defined by Equation 2. 
 Previous comparisons of the effects of conventional and atypical  
antipsychotics on progressive-ratio schedule performance found that the two classes 
of drugs exerted different patterns of effect on the parameters of Equation 1 (Mobini 
et al. 2000; Zhang et al. 2005a). Atypical  antipsychotics increased the values of both 
the „specific activation‟ parameter, a, and the „response time‟ parameter, δ; in 
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contrast, conventional antipsychotics increased δ, but either reduced or had no effect 
on a. The present results are consistent with these previous findings, in that clozapine 
increased both a and δ, whereas haloperidol increased δ and reduced a.   
The parameter a is believed to provide a quantitative measure of the efficacy 
or value of reinforcers (Killeen 1994; Bizo and Killeen 1997; Killeen and Sitomer 
2003; Reilly 2003; Kheramin et al. 2005; Bezzina et al. 2008a, 2008b; Killeen et al. 
2009; Rickard et al. 2009). Thus the opposite effects of clozapine and haloperidol on 
this parameter are consistent with the notion that clozapine increased and haloperidol 
reduced the incentive value of the food reinforcer. The decay parameter, b, of 
Equation 2 is also related to incentive value (Rickard et al. 2009). Clozapine tended to 
increase this parameter, although the effect was not statistically significant, whereas 
haloperidol significantly reduced it.  
The apparent enhancement of the incentive value of food reinforcers by 
clozapine may be related to this drug‟s known food intake-enhancing effect (Comer et 
al. 1997; Hartfield et al. 2003; Goudie et al. 2007). The mechanism underlying this 
effect is uncertain. Clozapine has a complex receptor binding profile which includes 
notably high affinities for 5-HT2A, histamine H1 and muscarinic M1 receptors 
(Bymaster 1996); it has been suggested that the combined blockade of all these 
receptors is responsible for the hyperphagic effects of this drug (Hartfield et al. 2003).  
A reduction of the incentive value of food reinforcers by haloperidol is 
consistent with the well known „anhedonia theory‟ which posits that conventional 
antipsychotics reduce the rewarding value of food and other reinforcers by blocking 
dopamine D2 receptors in limbic structures (Wise 1982, 2006). Evidence consistent 
with an antihedonic effect of conventional antipsychotics derives from a wide variety 
of behavioural approaches, including operant response rate measures (Heyman 1983; 
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Morley et al. 1984; Salamone 1987), conditioned reinforcement paradigms (Cador et 
al. 1991), and the rate of extinction of operant responses (Wise et al. 1978; Salamone 
1986). In some cases, these observations may be susceptible to an alternative 
interpretation in terms of a motor debilitating effect of the drugs (see Salamone et al. 
1994, 1997). Quantitative analysis of schedule-controlled behaviour based on 
Killeen‟s (1994) MPR model enables these two processes to be separated 
mathematically. Previous applications of this method indicated a predominant effect 
of haloperidol on motor capacity (Mobini et al. 2000; Zhang et al. 2005a). However, 
the present results indicate that haloperidol also produced a substantial reduction of 
the incentive value of the food reinforcer. 
Since δ is believed to be inversely related to the motor capacity of the 
organism (Killeen 1994; Bizo and Killeen 1997; Killeen and Sitomer 2003; Reilly 
2003; Kheramin et al. 2005; Bezzina et al. 2008a, 2008b; Killeen et al. 2009; Rickard 
et al. 2009), the increase in this parameter produced by both clozapine and haloperidol 
is consistent with an adverse effect of both drugs on motor functioning. The parameter 
Ri of Equation 2 may also be related to motor functioning, since it expresses the 
maximum rate of emission of trains of operant responses; however, unlike δ, it is not 
influenced by the post-reinforcement pause, which may in part reflect post-prandial 
effects of the reinforcer (Rickard et al. 2009). Both clozapine and haloperidol tended 
to reduce this parameter, the effect being statistically significant only in the case of 
clozapine.  
The apparent motor debilitating effects of clozapine and haloperidol are 
unlikely to reflect the same underlying process. In clozapine‟s case the effect may be 
related to sedation, a known side-effect of this drug which is generally attributed to 
the blockade of central H1 receptors (King and Waddington 2004). Haloperidol‟s 
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effect on the motor parameters of Equations 1 and 2 is more likely to reflect blockade 
of D2 receptors in the basal ganglia, the basis of the ubiquitous extrapyramidal motor 
side-effects of conventional antipsychotics (Cunningham Owens 1999).   
Both clozapine and haloperidol produced modest increases in the value of the 
currency parameter, β, although this effect only reached statistical significance in the 
case of clozapine. The interpretation of this finding is unclear. Increases in this 
parameter have been found to occur following increases in reinforcer size (Bizo et al. 
2001; Bezzina et al. 2008a; Rickard et al. 2009), possibly reflecting the propensity of 
larger reinforcers to induce more effective response-reinforcer coupling (Killeen 
1994; Bizo et al. 2001; Rickard et al. 2009). This might suggest that clozapine 
increased the efficiency of response-reinforcer coupling in this experiment. However, 
we are reluctant to attribute theoretical significance to the present finding, because 
previous experiments have not generally found reliable effects of clozapine and other 
antipsychotics on this parameter (Mobini et al. 2000; Zhang et al. 2005a, 2005b). 
The main purpose of this experiment was to compare the effects of 
cyproheptadine and clozapine on progressive-ratio schedule performance. The results 
indicate that the two drugs had similar profiles of effect on the parameters of 
Equations 1 and 2. On the basis of the theoretical interpretation of these parameters 
discussed above, the present results are thus consistent with the notion that 
cyproheptadine, like clozapine, increased the incentive value of the food reinforcer 
and induced a degree of motor debilitation. An increase in the incentive value of food 
reinforcers by cyproheptadine may be related to the known food intake-enhancing 
effect of this drug, an effect that it shares with clozapine (Hartfield et al. 2003; Goudie 
et al. 2007). It has been proposed that the hyperphagic effects of both drugs reflect the 
combined blockade of central 5-HT2A, H1 and M1 receptors (Hartfield et al. 2003; 
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Goudie et al. 2007). The apparent motor debilitating effects of both drugs (increase in 
δ and reduction of Ri) may reflect sedation which may be attributable to H1 receptor 
blockade in both cases.  
The similar pharmacological profiles of cyproheptadine and clozapine have led 
to the suggestion that cyproheptadine may be of value in the management of 
schizophrenia when given in conjunction with a conventional antipsychotic, 
particularly in the case of patients for whom negative symptoms are especially 
troublesome. Although attempts to verify this proposal in clinical studies have so far 
yielded mixed results (see Introduction), the finding that cyproheptadine, like 
clozapine, may enhance incentive reinforcer value suggests that further clinical studies 
in studies in which cyproheptadine supplements a conventional antipsychotic may be 
worthwhile (see Goudie et al. 2007). It must be emphasized, however, that the present 
results were obtained exclusively with food reinforcers, and it remains to be 
established whether cyproheptadine‟s and clozapine‟s effects reflect interactions with 
general reward processes, rather than with mechanisms specific to food reinforcement. 
Further experimental work is needed in order to address this matter. 
Combined treatment with cyproheptadine and haloperidol was not tested in 
these experiments. It would be of interest, in future experiments, to examine the effect 
of this treatment combination on different behavioural paradigms, in view of the 
suggestion that combined treatment with cyproheptadine and a conventional 
antipsychotic may confer some advantages in the management of schizophrenia (see 
above). However, it is questionable whether the progressive-ratio schedule would be 
the ideal model for assessing the utility of this treatment. The putative clinical value 
of this treatment approach resides in the combination of a drug that may alleviate 
anhedonia and other negative symptoms (i.e cyproheptadine) and a drug with known 
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ability to suppress positive symptoms (i.e. haloperidol). The quantitative analysis of 
progressive-ratio schedule performance adopted here provides a means of assessing 
the incentive value of positive reinforcers, and may therefore provide a useful measure 
of the propensity of drugs to alleviate negative symptoms; however it offers no 
insights into ability of drugs to suppress positive psychotic symptoms.  
Chlordiazepoxide‟s effect on the parameters of Equations 1 and 2 is consistent 
with an increase in the incentive value of the reinforcer (increases in a and b). 
However, unlike clozapine and cyproheptadine, its effect is not suggestive of motor 
impairment; indeed the lower dose actually reduced δ and increased Ri, suggesting a 
modest facilitation of operant responding. The increase in reinforcer value may be 
related to chlordiazepoxide‟s known ability to facilitate feeding in rodents (Berridge 
and Treit, 1986; Freet et al. 2006). The mechanism underlying benzodiazepines‟ 
appetite-enhancing effect is uncertain. However, since the main pharmacological 
action of these drugs is to facilitate γ-aminobutyric acid (GABA)-mediated functions, 
and they do not interact directly with 5-HT2A or H1 receptors (Cooper 2004), the 
mechanism proposed to account for clozapine‟s and cyproheptadine‟s effects on food 
intake and incentive value is unlikely to be responsible for chlordiazepoxide‟s effects.  
THC had no significant effect on performance on the progressive-ratio 
schedule. This negative result was unexpected in view of THC‟s known appetite-
stimulating effect (Abel 1975; Williams et al. 1998; Williams and Kirkham 1999) and 
previous reports of its ability to increase the breakpoint in progressive-ratio schedules 
(Higgs et al. 2005). It is possible that the doses used in this experiment were 
inadequate to alter the incentive value of the food reinforcer. However, these doses 
were selected on the basis of previous studies that reported increases in food intake 
(Higgs et al. 2005; Jarrett et al. 2005). The effect of cannabinoids on food 
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reinforcement is known to differ between different foodstuffs, being especially 
pronounced in the case of sweet foods (Ward and Dykstra 2005). The reinforcer 
pellets used in these experiments are more palatable than standard laboratory chow, 
but have no sucrose or other carbohydrate content (TestDiet published data). It may be 
of interest in future experiments to compare the effects of THC on the parameters of 
Equation 1 using progressive-ratio schedules employing carbohydrohydrate 
reinforcers. 
The present findings provide a further illustration of the implications of 
Killeen‟s (1994) MPR model for interpretating the effects of neuropharmacological 
interventions on progressive-ratio schedule performance (for review, see Killeen et al. 
2009; Rickard et al. 2009). According to MPR, the traditional index of performance 
on this schedule (the breakpoint) is a hybrid measure, being jointly determined by the 
incentive value of the reinforcer, represented by a, and the motor limitations of the 
organism, represented by δ. The estimated value of the breakpoint, derived by 
extrapolation of the descending limb of the response rate function, is defined as a/δ. In 
the case of interventions that have little impact on motor performance, changes in the 
breakpoint may provide a reliable indication of changes of incentive value. However, 
an effect on motor performance may augment, attenuate or even completely override 
the impact of a change of incentive value on the breakpoint. In the present 
experiments, there was a general tendency for changes in a to coincide with changes 
in the breakpoint. For example both doses of cyproheptadine and the lower dose of 
chlordiazepoxide increased a and the breakpoint, whereas haloperidol produced dose-
dependent reductions of  both these measures. Clozapine, however, did not 
significantly alter the breakpoint, evidently because the effects of the drug on a and δ 
exerted opposing influences on the breakpoint.  
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The breakpoint also presents practical difficulties for the behavioural 
pharmacologist. It is usual to describe the breakpoint as the response/reinforcer ratio 
at which responding ceases. However, the operational definition of  the cessation of 
responding is arbitrary, and different criteria have been adopted by different workers 
(see Killeen et al. 2009). Moreover, allowing the experimental session to become 
extended for an indefinite period until the breakpoint is reached can result in test 
periods that differ in length between subjects and conditions, clearly a complicating 
factor when the effects of acute drug treatments are compared. In the present 
experiments, as in many previous studies (e.g. Aberman et al. 1998; Zhang et al. 
2005a, 2005b), time-constrained sessions were used. Although this avoids the 
problem of variable session length, it results in the formal breakpoint criterion (in the 
present case, 5 minutes without responding) not being attained by all subjects in all 
sessions, and necessitates either the elimination of data from sessions in which the 
criterion was not reached or the use of some other measure, such as the highest ratio 
completed within the time-constrained session. As shown in Table 1, there was a 
general tendency for increases in the highest completed ratio and the breakpoint to be 
associated with a reduction of the percentage of sessions in which the breakpoint 
criterion was reached.  As argued elsewhere (Killeen et al. 2009; Rickard et al. 2009), 
the mathematical approach exemplified by MPR, by deriving parameter estimates for 
individual subjects, avoids many of the practical, as well as the theoretical difficulties 
associated with the use of  the breakpoint. 
The theoretical basis of the mathematical analysis employed in these 
experiments deserves some comment. Killeen‟s (1994) model, from which Equation 1 
is derived, is based on a coherent set of principles that are proposed to determine 
characteristic patterns of responding generated by different schedules of 
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reinforcement. These principles include the activation of behaviour by reinforcers 
(reflected in a), biological constraints on response rate (reflected in δ), and the 
coupling of operant responses to reinforcers (reflected in β) . As reviewed above,  
Equation 1 has been found to provide a satisfactory account of overall response rate in 
progressive-ratio schedules in a number of previous studies. However, its failure to 
provide an adequate description of running response rate in these schedules prompted 
Rickard et al. (2009) to propose Equation 2 as an empirical descriptor of running rate. 
Although the present data confirm the utility of both equations to describe the effects 
of drugs on schedule-controlled behaviour, it must be acknowledged that the use of 
separate models to describe the overall and running response rates, one theoretically 
based and the other essentially descriptive, is less than satisfactactory. An integrated 
mathematical account of the two performance measures will be an important goal of 
the future development of Killeen‟s MPR model (Killeen 1994;  Killeen et al. 1999). 
  In summary, the present results confirm the differing effects of haloperidol 
and clozapine on progressive-ratio schedule performance, and provide further 
indication that cyproheptadine‟s behavioural effects in rats resemble those of 
clozapine. Quantitative analysis based on Killeen‟s (1994) theoretical model of 
schedule-controlled behaviour, MPR, indicated that both clozapine and 
cyproheptadine enhanced the incentive value of the food reinforcer and induced some 
degree of motor impairment. The results further confirm the utility of quantitative 
analysis of progressive-ratio schedule performance based on MPR for investigations 
of the effects of drugs on motivational processes (Killeen et al. 2009; Rickard et al. 
2009). 
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Table 1.   Peak response rate, breakpoint and highest completed ratio under each treatment 
condition (mean ± SEM) 
 
a
  Percentage of sessions in which the breakpoint criterion was reached (see text) 
* Significance of difference from vehicle control, P<0.05 (see text for details) 
 Peak response rate Breakpoint Percent Highest  
Treatment (responses min
-1
) (ratio) breakpoint
a
 completed ratio 
Cyproheptadine                            
   vehicle 129.1 ± 5.2  116.8 ± 13.8 
 
 82.9 ± 7.5  135.7 ± 16.9 
   1 mg kg
-1 
132.0 ± 6.1  140.6 ± 16.0  62.5 ± 10.5*  186.3 ± 20.5* 
   5 mg kg
-1 
102.1 ± 6.6*  189.0 ± 33.3*  26.4 ± 9.3*  226.5 ± 29.3* 
Clozapine                
   vehicle 92.4 ± 6.7  125.9 ± 10.7  91.7 ± 5.8  134.5 ± 10.6 
   3.75 mg kg
-1 
82.6 ± 7.7  135.5 ± 16.4  88.1 ± 7.5  163.6 ± 19.8 
   7.5 mg kg
-1 
70.4 ± 5.5*  137.7 ± 16.8  79.8 ± 8.6  159.8 ± 18.1 
Haloperidol                
   vehicle 108.1 ± 9.5  126.8 ± 18.9  82.5 ± 10.1  208.0 ± 39.6 
   0.05 mg kg
-1 
97.7 ± 7.1  59.8 ± 7.4*  77.3 ± 9.8  112.2 ± 27.0* 
   0.1 mg kg
-1 
78.8 ± 7.4*  20.1 ± 2.5*  100.0 ± 0.0*  28.7 ± 5.9* 
Chlordiazepoxide               
   vehicle 126.0 ± 6.1  105.2 ± 13.5  88.5 ± 6.4  120.4 ± 16.2 
   3 mg kg
-1 
145.4 ± 8.7*  151.4 ± 18.8*  63.3 ± 10.1*  178.7 ± 20.8* 
   10 mg kg
-1 
127.5 ± 9.6  116.9 ± 15.3  80.0 ± 4.9  161.3 ± 21.7* 
THC                
   vehicle 134.5 ± 7.8  105.8 ± 14.3  92.7 ± 5.0  127.4 ± 18.2 
   1 mg kg
-1 
131.4 
 
± 7.4  112.5 ± 15.5  85.8 ± 7.8  134.0 ± 19.9 
   3 mg kg
-1 
133.6 ± 7.0  108.9 ± 13.1  81.3 ± 7.9*  127.4 ± 17.5 
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Table 2.  Parameters of Equation 1 (group mean data ± SEM)  
Treatment a (s)  δ (s)  β 
Cyproheptadine            
   vehicle 116.6 ± 12.2  0.69 ± 0.06  0.57 ± 0.09 
   1 mg kg
-1 
151.0 ± 20.8  0.65 ± 0.08  0.45 ± 0.08 
   5 mg kg
-1 
315.2 ± 64.3*  0.88 ± 0.07*  0.46 ± 0.08 
Clozapine            
   vehicle 174.7 ± 22.8  0.92 ± 0.09  0.37 ± 0.09 
   3.75 mg kg
-1 
303.7 ± 39.3*  1.19 ± 0.10  0.53 ± 0.10 
   7.5 mg kg
-1 
470.9 ± 84.5*  1.41 ± 0.24*  0.57 ± 0.10* 
Haloperidol            
   vehicle 252.7 ± 65.0  0.97 ± 0.10  0.36 ± 0.09 
   0.05 mg kg
-1 
156.4 ± 53.6*  1.11 ± 0.12  0.51 ± 0.09 
   0.1 mg kg
-1 
40.2 ± 6.7*  1.20 ± 0.16*  0.63 ± 0.12 
Chlordiazepoxide            
   vehicle 101.6 ± 13.0  0.67 ± 0.06  0.42 ± 0.09 
   3 mg kg
-1 
124.9 ± 15.1  0.56 ± 0.03*  0.56 ± 0.07 
   10 mg kg
-1 
135.6 ± 15.4*  0.70 ± 0.06  0.67 ± 0.08 
THC            
   vehicle 106.9 ± 13.1  0.72 ± 0.11  0.57 ± 0.08 
   1 mg kg
-1 
122.0 ± 16.6  0.68 ± 0.08  0.48 ± 0.07 
   3 mg kg
-1 
101.7 ± 10.3  0.73 ± 0.13  0.52 ± 0.08 
 
* Significance of difference from vehicle control, P<0.05 (see text for details) 
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Table 3.  Parameters of Equation 2 (group mean data ± SEM)  
Treatment Ri (responses min
-1
)  b  c 
Cyproheptadine            
   vehicle 222.0 ± 19.1  30.0 ± 13.1  1.43 ± 0.20 
   1 mg kg
-1 
191.7 ± 15.9  66.9 ± 12.9  1.40 ± 0.11 
   5 mg kg
-1 
151.9 ± 19.2*  85.0 ± 27.0  2.47 ± 0.84 
Clozapine            
   vehicle 154.5 ± 10.8  59.4 ± 8.8  1.61 ± 0.21 
   3.75 mg kg
-1 
138.7 ± 14.1  66.5 ± 12.3  1.40 ± 0.16 
   7.5 mg kg
-1 
107.3 ± 11.4*  72.3 ± 14.4  2.21 ± 0.72 
Haloperidol            
   vehicle 158.1 ± 15.9  59.5 ± 9.6  1.31 ± 0.12 
   0.05 mg kg
-1 
148.1 ± 13.1  37.3 ± 9.4  1.78 ± 0.20 
   0.1 mg kg
-1 
133.4 ± 17.4  14.5 ± 2.3*  3.88 ± 0.75* 
Chlordiazepoxide            
   vehicle 208.1 ± 20.2  51.6 ± 13.7  1.84 ± 0.40 
   3 mg kg
-1 
210.7 ± 17.7  57.7 ± 10.8  1.44 ± 0.21 
   10 mg kg
-1 
186.5 ± 15.0  53.4 ± 12.4  1.36 ± 0.15 
THC            
   vehicle 207.2 ± 20.1  48.2 ± 7.9  1.73 ± 0.19 
   1 mg kg
-1 
201.8 ± 16.0  53.8 ± 11.4  1.82 ± 0.23 
   3 mg kg
-1 
189.5 ± 9.5  57.0 ± 9.7  1.87 ± 0.11 
 
* Significance of difference from vehicle control, P<0.05 (see text for details) 
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Figure 1. Effects of cyproheptadine (CYPRO) on progressive-ratio schedule performance. 
Left-hand graph: relation between overall response rate and the response/reinforcer ratio, N. 
Unfilled circles: vehicle-alone treatment; upright filled triangles: cyproheptadine 1 mg kg
-1
; 
inverted filled triangles: cyproheptadine 5 mg kg
-1
 (see inset). Curves are fits of Equation 1 
to the data. Right-hand graph: relation between running response rate and N. The curves are 
fits of Equation 2 to the data; other conventions are as in the left-hand graph.  
 
Figure 2. Effects of clozapine (CLOZ) on progressive-ratio schedule performance. Unfilled 
circles: vehicle-alone treatment; upright filled triangles: clozapine 3.75 mg kg
-1
; inverted 
filled triangles: clozapine 7.5 mg kg
-1
 (see inset). Other conventions are as in Fig. 1.  
  
Figure 3. Effects of haloperidol (HAL) on progressive-ratio schedule performance. Unfilled 
circles: vehicle-alone treatment; upright filled triangles: haloperidol 0.05 mg kg
-1
; inverted 
filled triangles: haloperidol 0.1 mg kg
-1
 (see inset). Other conventions are as in Fig. 1. 
 
Figure 4. Effects of chlordiazepoxide (CDP) on progressive-ratio schedule performance. 
Unfilled circles: vehicle-alone treatment; upright filled triangles: chlordiadepoxide 3 mg 
kg
-1
; inverted filled triangles: chlordiazepoxide 10 mg kg
-1
 (see inset). Other conventions 
are as in Fig. 1. 
 
Figure 5. Effects of Δ9-tetrahydrocannabinol (THC) on progressive-ratio schedule 
performance. Unfilled circles: vehicle-alone treatment; upright filled triangles: THC 1 mg 
kg
-1
; inverted filled triangles: THC 3 mg kg
-1
 (see inset). Other conventions are as in Fig. 1. 
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Fig. 5 
